深圳惠善生物科技

Shenzhen Huishan Biotechnology is a biopharmaceutical company specializing in the development of advanced exosome-based therapeutic platforms. Based in Shenzhen, China, the company focuses on leveraging extracellular vesicles (EVs) as a next-generation delivery system for various therapeutic cargoes, including nucleic acids and proteins. Their technology aims to enhance the precision of drug targeting while minimizing systemic toxicity, particularly in the fields of oncology and immunology. Huishan Biotech integrates bioengineering and nanotechnology to optimize exosome loading and surface modification for tissue-specific delivery. The company is currently advancing several pre-clinical programs designed to address unmet medical needs in solid tumors and chronic inflammatory conditions.